[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Cleveland Clinic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":632},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,101,0,25,[9,43,73,98,116,138,161,186,206,232,260,285,303,324,347,370,396,430,455,477,496,519,546,569,602],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100636917","health-related-quality-of-life-and-metabolic-outcomes-in-pcos-100636917",false,"NCT07571915","Health-Related Quality of Life and Metabolic Outcomes in PCOS","Health-Related Quality of Life and Metabolic Outcomes in PCOS: A Feasibility Study of Comprehensive PCOS Education and Lifestyle Modification Support Delivered Via Synchronous Virtual Groups","Inclusion Criteria:\n\n1. Non-pregnant females ages 18-49 years\n2. Preexisting diagnoses of PCOS and obesity (body-mass index (BMI) equal or greater to 30 kg\u002Fm2) at enrollment\n\nExclusion Criteria:\n\n1. Patients who are pregnant or planning to become pregnant during the study period\n2. Patients currently or with recent participation (\\\u003C 12 months at the time of enrollment) in a PCOS-focused group\n3. Patients with documented monogenic obesity\n4. Patients with a diagnosis of any type of diabetes (with the exclusion of prediabetes)\n5. Patients on systemic glucocorticoid therapy \\> 7 days at the time of enrollment\n6. Patients with any end-stage organ disease\n7. Patients without access to internet\n8. Patients requiring English language interpretation\n9. Any condition which, based on the investigator's medical judgment, would preclude patient ability to complete the study",true,"FEMALE","18 Years","49 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","The primary outcome of interest is change in PCOS health-related quality of life, while the secondary outcome of interest is change in adiposity, cardiometabolic, and inflammation biomarkers.",[29],"PCOS (Polycystic Ovary Syndrome)","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-01","ACTUAL",{"date":36,"type":34},"2026-06-01",{"date":38,"type":23},"2027-12-31",{"name":40,"class":41},"The Cleveland Clinic","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100645243","ultrasound-guided-versus-standard-margin-selection-in-ileocecal-resection-of-terminal-ileal-cd-100645243","NCT07680283","Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD","Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal Crohn's Disease: A Phase II Randomized Trial","SMILE-CD","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Diagnosis of terminal ileal Crohn's disease with inflammatory or fibrostenotic phenotype localized to terminal ileum\u002Fileocecal region and assessed on either preoperative imaging or during surgical exploration at the time of surgery.\n* Scheduled to undergo primary ileocolic resection.\n\nExclusion Criteria:\n\n* Penetrating disease with abscess or complex fistula requiring complex resection.\n* Prior ileocolic resection.\n* Diagnosis of Crohn's colitis.\n* Pregnancy or inability to provide informed consent.\n* Stoma at or before randomization: Participants in whom a stoma is required before randomization (identified intra-operatively) will not be randomized and will be excluded from the trial. Stoma after randomization: If a stoma is created after randomization-either during the index operation or at re-operation for postoperative complications-the participant remains in the trial. All feasibility, histopathology, operative, and safety outcomes will be collected and analyzed in the assigned arm (ITT). However, these participants will not be evaluable for the endoscopic-recurrence endpoint; they will be listed as \"not assessed for endoscopic recurrence (stoma)\" with reasons documented.\n* Contraindication to IOUS (as determined by the surgeon).","ALL",{"count":53,"type":23},44,[26],"This is a Phase II, single-center (Cleveland Clinic), two-arm, randomized, parallel-group superiority trial. The two arms will compare IOUS-guided margin selection against standard macroscopic margin selection in patients undergoing ileocolic resection for terminal ileal Crohn's disease. Patients and outcome assessors (pathologists, endoscopists) will be blinded to the intervention arm, while surgeons, by the nature of the intervention, cannot be blinded. Randomization will be computer-generated with concealed allocation using permuted blocks to ensure balanced group sizes.",[57],"Crohn's Disease (CD)",[59,60,61,62,63,64],"Ultrasound","ileocecal resection","anastomosis","resection margin","ileocolic resection","Crohn's disease","2026-06-29",{"date":67,"type":34},"2026-07-02",{"date":69,"type":23},"2026-07",{"date":71,"type":23},"2029-01",{"name":40,"class":41},{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":17,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100645278","cognitive-and-immunologic-profiles-of-patients-with-olfactory-dysfunction-after-smell-training-100645278","NCT07681973","Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training","CIPOD","Inclusion Criteria:\n\n* Age less than 18 years-old\n* Present to rhinology clinic with CRS with nasal polyps\n* Sense of smell loss for any reason (other than trauma or tumor)\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years of age\n* Individuals with unilateral nasal polyps\n* Autoimmune diseases\n* Ciliary disorders\n* Cystic fibrosis\n* Smell loss due to tumors or trauma",{"count":81,"type":23},52,[26],"A research study to assess the baseline olfactory function, mental health status, clinical severity, and immunological profile in patients with smell loss. The impact of a 3-month olfactory training program on smell function, immunological changes, and mental health in patients with smell loss will be evaluated.\n\nThe primary purpose of this study is to investigate tissue and blood samples to identify molecules that may be related to smell loss, ultimately aiming to develop future treatments for this condition and correlate with cognition.",[85,86],"Smell Loss","Chronic Rhinosinusitis (CRS)",[85,88,89,90],"Chronic Rhinosinusitis","Nasal Polyps","CRSwNP","2026-06-26",{"date":67,"type":34},{"date":94,"type":34},"2025-12-09",{"date":96,"type":23},"2027-03-31",{"name":40,"class":41},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":42},"100515595","randomized-controlled-trial-of-miniaturized-percutaneous-nephrolithotomy-with-vacuum-assisted-access-sheaths-versus-conventional-sheaths-for-treatment-of-nephrolithiasis-100515595","NCT05993546","Randomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis","Inclusion Criteria:\n\n* Patients with planned prone mini-PCNL and a preoperative NCCT\n* Primary stone size: 10-25 mm\n* Pre-existing indwelling nephrostomy tube or ureteral stent permitted\n* Age: ≥ 18 years old\n* Gender: all\n* Ethnicity: all\n* Capable of giving informed consent\n* Capable and willing to fulfill requirements of the study\n\nExclusion Criteria:\n\n* Anticoagulated or history of coagulopathy\n* Congenital renal anomalies\n* Prior ipsilateral upper urinary tract reconstructive procedures\n* Conversion to open procedure\n* Multiple access tracts\n* Inability to give informed consent or unable to meet requirements of the study for any reason",{"count":105,"type":23},90,[26],"The purpose of this study is to compare two variations of the mini-PCNL procedure using either a vacuum-assisted sheath or standard sheath which are both used for the surgical treatment of kidney stones. Both procedure types are commonly used in the treatment of kidneys stones and they have been shown to be safe and effective in the treatment of stones similar in size and location to your own.",[109],"Kidney Stone",{"date":65,"type":34},{"date":112,"type":34},"2023-08-29",{"date":114,"type":23},"2026-12",{"name":40,"class":41},{"id":117,"slug":118,"hasResults":12,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":24,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":42},"100566639","physician-modified-endovascular-grafts-for-the-treatment-of-juxtarenal-aortic-aneurysms-100566639","NCT06657794","Physician Modified Endovascular Grafts for the Treatment of Juxtarenal Aortic Aneurysms","Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms","PMEG","Inclusion Criteria:\n\nAll patients must meet all of the following inclusion criteria to be eligible for enrollment into the study:\n\n1. Patient is ≥ 18 years of age\n2. Patients who are male or non-pregnant female (females of child bearing potential must have a negative pregnancy test prior to enrollment into the study)\n3. Patient or Legally Authorized Representative has signed an Institutional Review Board (IRB) approved Informed Consent Form\n4. Patient has a juxtarenal abdominal aortic aneurysm that meets at least one of the following:\n\n   1. An aneurysm with a maximum diameter of ≥ 5.5 cm for male (≥ 5.0 cm for female) or 2 times the normal diameter just proximal to the aneurysm using orthogonal (i.e., perpendicular to the centerline) measurements\n   2. Aneurysm with a history of growth \\> 0.5 cm in 6 months\n   3. Saccular aneurysm deemed at significant risk for rupture\n   4. Symptomatic aneurysm\n   5. Ruptured aneurysm\n5. Patient has patent iliac or femoral arteries, with or without the use of conduit, that will allow endovascular access with the physician modified endovascular graft.\n6. Patient has a suitable non-aneurysmal proximal aortic neck of ≥ 2 mm inferior to the most distal renal artery ostium.\n7. Patient has a suitable non-aneurysmal distal iliac artery length (seal zone) of ≥ 15mm. The resultant repair should preserve patency in at least one hypogastric artery.\n8. Patient has a suitable non-aneurysmal proximal aortic neck diameter between 20 and 32 mm, averaged across the diameters at the Celiac, SMA, at the lowest patent renal artery and at the midpoint of the renal arteries.\n9. Patient has suitable non-aneurysmal distal common iliac diameters between 8 and 20 mm.\n10. Patient has juxtarenal aortic neck angulation ≤ 60°\n11. Target branch vessel diameter ≥ 5 mm.\n12. Patient must be willing to comply with all required follow-up exams.\n\nExclusion Criteria:\n\nPatients that meet ANY of the following are not eligible for enrollment into the study:\n\n1. Patient has a mycotic aneurysm or has an active systemic or local infection that may increase the risk of endovascular infection\n2. Patient has unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina, or onset of prolonged angina)\n3. Patient has a major surgical or interventional procedure, not related to the endovascular repair, planned within +\u002F- 30 days of the AAA repair.\n4. Patient has history of an aortopathic connective tissue disease (e.g. Marfan's or Ehler's-Danlos syndrome).\n5. Patient has a known hypersensitivity or contraindication to anticoagulation or contrast media that is not amenable to pre-treatment.\n6. Patient has known allergy or intolerance to stainless steel, nitinol or gold (gold-coated tungsten).\n7. Patient has a body habitus that would inhibit X-ray visualization of the aorta\n8. Patient has a limited life expectancy of less than 1 year\n9. Patient is currently participating in another investigational device or drug clinical trial\n10. Patient has other medical, social or psychological conditions that, in the opinion of the investigator, preclude them from receiving the pretreatment, required treatment, and post-treatment procedures and evaluations.\n11. Thrombus or excessive calcification within the neck of the aneurysm\n12. Branch vessel stenosis ≥ 80%\n13. Patient treatable on label with FDA approved EVAR or FEVAR device and can wait for device availability.\n14. Subject is willing and eligible to enroll in a manufacturer-sponsored study at the investigational site, or the subject is willing and eligible to participate in a study with a manufacturer-made device at another institution.",{"count":125,"type":23},15,[26],"The primary objective of the clinical investigation \"Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms\" is to assess the use of the Physician-Modified Endovascular Grafts to repair juxtarenal aneurysms in high-risk subjects considered to be unsuitable candidates for open surgical repair, have limited or no other options for treatment, and having appropriate anatomy. The primary intent of the study is to assess safety and preliminary effectiveness of the device:\n\n* acutely (i.e., treatment success and technical success);\n* at 30 days (i.e., the rate of major adverse events (MAE)); and\n* at 6 months, 12 months and annually to 5 years (i.e., the proportion of treatment group subjects that achieve and maintain treatment success).",[129,130],"Juxtarenal Aortic Aneurysm","Aortic Rupture","2026-06-24",{"date":65,"type":34},{"date":134,"type":34},"2025-02-17",{"date":136,"type":23},"2030-12-31",{"name":40,"class":41},{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":17,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":42},"100559153","cardiovascular-and-metabolic-sciences-biorepository-100559153","NCT06560424","Cardiovascular and Metabolic Sciences Biorepository","Inclusion Criteria:\n\n* Willing and able to sign the informed consent document\n\nExclusion Criteria:\n\n* Chronic anemia (hemoglobin consistently \\\u003C9 g\u002FL)",{"count":145,"type":23},10000,"OBSERVATIONAL","The purpose of the Cardiovascular and Metabolic Sciences Biorepository is to collect and store information and biospecimens (blood, urine, stool, and heart tissue) from patients with and without cardiovascular and metabolic diseases to create a readily available biorepository of samples and related medical health information to expedite future research into the causes and consequences of cardiovascular and metabolic diseases.",[149,150],"Cardiovascular Diseases","Metabolic Disease",[152],"Biorepository","2026-06-23",{"date":155,"type":34},"2026-06-25",{"date":157,"type":34},"2024-09-18",{"date":159,"type":23},"2050-12-31",{"name":40,"class":41},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":17,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":24,"phases":170,"briefSummary":171,"conditions":172,"keywords":175,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":185,"locationsCount":42},"100210443","gut-flora-metabolite-reduction-after-dietary-intervention-grady-100210443","NCT02016430","Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)","GRADY","Inclusion Criteria:\n\nCohort 1 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Elevated TMAO metabolizers (\\>5 µM) based on screening test and\u002For eGFR \\\u003C 60 at most recent measurement.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol, which includes a 12-week dietary modification.\n\nCohort 2 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol.\n* eGFR values ranging from 16-59\n\nCohort 3 Inclusion criteria:\n\n* Men and women age 18 years or above.\n* Willing to remain on aspirin or able to be off aspirin or aspirin products for 1 week prior to starting the study and staying on the same aspirin regimen during the duration of the study.\n* Willing to sign the consent form and follow the study protocol.\n\nExclusion Criteria (all cohorts):\n\n* Significant chronic illness or end-organ dysfunction, including known history of uncompensated heart failure, renal failure, pulmonary disease, hematologic diseases.\n* Active infection or received antibiotics within 2 months of study enrollment\n* Use of over-the-counter probiotic within past month, or ingestion of yogurt within past 7 days\n* Having undergone bariatric procedures or surgeries such as gastric banding or bypass.\n* Pregnancy.\n* Any condition which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial",{"count":169,"type":23},170,[26],"Our group has recently identified the association between gut-flora-mediated carnitine and phosphatidylcholine metabolism, specifically trimethylamine-N-oxide (TMAO), and cardiovascular risk. This study investigates the ability for dietary intervention to modulate TMAO levels.",[173,174],"Dietary Modification","Cardiovascular Risk Factor",[176,177,178,179,180],"TMAO","Gut Flora","Dietary Intervention","Choline","Carnitine",{"date":155,"type":34},{"date":183,"type":34},"2014-04-04",{"date":114,"type":23},{"name":40,"class":41},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":24,"phases":194,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":202,"completionDateStruct":203,"leadSponsor":205,"locationsCount":42},"100642531","early-phase-1-self-start-triage-model-for-post-botox-lower-urinary-tract-symptoms-100642531","NCT07648290","Self-Start Triage Model for Post-Botox® Lower Urinary Tract Symptoms","Inclusion Criteria:\n\n* Female patients of all races and ethnicities aged 18 years and older.\n* Diagnosis of Overactive Bladder (OAB) and\u002For Urge Urinary Incontinence (UUI).\n* Scheduled to receive intradetrusor onabotulinumtoxinA (Botox®) for symptom management.\n* Has decision making capacity to provide informed consent and comply with and follow study protocols.\n* Ability to navigate a computer system independently\n* Access to MyChart and email account\n\nExclusion Criteria:\n\n* Patients who currently perform Clean Intermittent Catheterization (CIC) or have an indwelling catheter.\n* History of Severe Renal Impairment Cr\u002FCl - \\\u003C60 ml\u002Fmin 1.73m2\n* History of recurrent UTIs (defined as \\>3x symptomatic UTIs in 12 months).\n* Post-Void Residual (PVR) volume \\>150 mL.\n* Active UTI at the time of procedure (procedure cancellation criteria).\n* Patients currently on prophylactic antibiotics.\n* Inability to provide informed consent.",{"count":193,"type":23},260,[195],"EARLY_PHASE1","The primary objective of this study is to investigate whether providing a standing, take-home prescription for empiric Macrobid (self-start model) is superior to standard call-in\u002Furgent care triage (triage model) among patients undergoing intradetrusor Botox®. Urinary tract infections. (UTIs) are the most common complication with intradetrusor Botox®, and patients have to call in to the triage line or present to a health care facility to be evaluated. Thus, the research team will compare Unplanned Healthcare Utilization, i.e. the frequency of triage calls, MyChart messages, Urgent Care visits, and Emergency Department visits related to urinary symptoms, between participants in the self-start intervention group and those in the triage control group. The team hypothesizes that patients in the \"self-start\" intervention group will demonstrate a lower frequency of healthcare utilization events when compared to those in the standard of care control.",[198],"Overactive Bladder","NOT_YET_RECRUITING","2026-06-22",{"date":155,"type":34},{"date":33,"type":23},{"date":204,"type":23},"2028-03-31",{"name":40,"class":41},{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":12,"sex":51,"minAge":214,"maxAge":4,"enrollmentInfo":215,"targetDuration":4,"studyType":24,"phases":217,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":42},"100603595","phase-4-boost-pd-a-naturalistic-study-on-ipx-203-for-parkinsons-disease-100603595","NCT07138560","BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease","BOOST-PD - Better On-time Observations of Motor Fluctuations Using Wearable Sensor Technology: A Naturalistic Study on IPX-203 for Parkinson's Disease","BOOST-PD","Inclusion Criteria:\n\n* \\- Participant is 40 years or older\n* Diagnosed with idiopathic Parkinson's disease and is deemed to be levodopa responsive\n* Baseline MDS-UPDRS score in OFF-state is \\> 20\n* Patient is being treated with a stable regimen of CD-LD for at least four weeks\n* The minimum most frequent levodopa dosing is 100 mg if using IR CD-LD and 195mg if using Rytary; maximum levodopa dosing per day is 1200 mg if using IR CD-LD, 1000 mg if associated with a COMT inhibitor, and 2400 mg if using Rytary\n* Participant can be on stable doses of any levodopa adjunctive medications and\u002For psychotropic medications for at least 30 days\n* Participant experiences off time estimated at 2 hours or more per day; participant can comply with the wearable kinematic device.\n\nExclusion Criteria:\n\n* \\- Participants with severe dyskinesia as defined by a score of 4 on Question 4.1 (time spent with dyskinesia) of UPDRS IV\n* Currently on device-aided therapies for advanced PD\n* Using controlled-release CD-LD apart from a single daily bedtime dose\n* Using \"on demand\" therapy unless willing to stop it during the study period\n* Have a diagnosis hypothesis of dopamine dysregulation syndrome or evidence of significant levodopa-related complications including orthostatic hypotension or psychosis\n* History of dementia or MOCA score lower than 23\n* Significant medical history might interfere significantly with study participation\n* Being enrolled in other clinical trials involving active medication interventions.","40 Years",{"count":216,"type":23},22,[218],"PHASE4","The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias. The change in the duration and quality of on-time will be measured by a wearable device placed on your wrist called KinesiaU.",[221],"Parkinson Disease",[223,224],"Crexont","motor fluctuations","2026-06-18",{"date":153,"type":34},{"date":228,"type":34},"2025-07-24",{"date":230,"type":23},"2027-05-15",{"name":40,"class":41},{"id":233,"slug":234,"hasResults":12,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":242,"conditions":243,"keywords":247,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":42},"100642184","dietary-tracking-in-heart-failure-100642184","NCT07649148","Dietary Tracking in Heart Failure","Dietary Optimization Through Tracking and Integrated Evaluation","DOTTIE","Inclusion Criteria:\n\n* Adults (≥18 years) with NYHA Class II-III HF\n* Able to use Cronometer to track dietary intake and able to prepare food at home independently (able to modify dietary intake)\n\nExclusion Criteria:\n\n* History of heart transplant or LVAD implant\n* Unable or unwilling to follow dietary coaching for UPF reduction\n* eGFR \\\u003C30 ml\u002Fkg\u002F1.73m2",{"count":241,"type":23},60,"Emerging evidence links ultra processed foods (UPFs) to adverse cardiovascular outcomes. UPFs are often high in sodium, unhealthy fats and added sugars, while being low in essential nutrients and fiber. UPFs contribute to systemic inflammation, fluid retention, and metabolic dysfunction-key drivers of HF and kidney disease progression. Traditional dietary counseling often lacks specificity around food processing levels. Furthermore, the majority of nutrition studies relied on extensive self-reported dietary recall food frequency questionnaires (FFQ) that are subjective, often labor intensive, and difficult to implement practically in the clinical setting. As such, researchers have developed metabolite scores from blood and urine samples to help quantify UPF consumption, which has the promise to better guide dietary counseling and track process. Therefore, the aim of this study is to evaluate the feasibility and physiological impact of a structured UPF-reduction dietary intervention in patients with HF, leveraging both digital dietary tools (Cronometer) and biomarker assessments.",[244,245,246],"Heart Failure","NYHA Class II Heart Failure","NYHA Class III Heart Failure",[248,249,244,250,251],"Diet Tracking","Diet","Cronometer","Ultra Processed Food","2026-06-15",{"date":254,"type":34},"2026-06-17",{"date":256,"type":23},"2026-06",{"date":258,"type":23},"2040-06",{"name":40,"class":41},{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":268,"enrollmentInfo":269,"targetDuration":271,"studyType":146,"phases":4,"briefSummary":272,"conditions":273,"keywords":274,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":283,"leadSponsor":284,"locationsCount":42},"100642964","wearable-technology-in-heart-failure-patients-100642964","NCT07650669","Wearable Technology in Heart Failure Patients","Integration of Wearable Technology Data in Patients With or at Risk of Heart Failure","Wearables-HF","Inclusion Criteria:\n\n* Participants must be between 18 and 85 years of age.\n* Participants must have a diagnosis of heart failure or be identified as at risk of developing heart failure.\n* Participants must either own or be willing to acquire a compatible personal consumer-grade wearable device (such as Fitbit and Apple Watch) and must enroll via the HeartBit app.\n\nExclusion Criteria:\n\n* Individuals presenting with cognitive impairments or mental incapacity that would impede their understanding of, or cooperation with, the study protocol.","85 Years",{"count":270,"type":23},500,"2 Years","The primary objective is to establish a Cleveland Clinic-led registry designed to integrate continuous physiological data from consumer wearables, captured by the HeartBit app and a Case Western Reserve University (CWRU)-based platform, with clinical data from patients' individual Electronic Health Record (EHR). This proposal is for understanding the use of personal wearable devices (such as: Fitbit, and Apple Watch) to gather physiological data (such as: heart-rate, steps taken, sleep cycles, and calories expended) and correlate those data with self-reported health status. The research team intends to collect all of the data generated by the participant's personal wearable devices and to perform an integrated analysis of the physiological data generated by the wearable devices. The investigators specifically aim to uncover patterns from the data that they can evolve models from. The investigators' goal is to better predict and diagnose the adverse effects associated with daily lifestyle, including cardiovascular risk, musculoskeletal, metabolic risks, stress, and sleep disturbances. These data may be used to better understand the daily habits and lifestyle choices to possibly predict a person's health and disease risk to provide a more comprehensive diagnosis with early recognition and prevention. As wearable devices become more accurate and cheaper to purchase for the general public, integrative analysis of wearable data from multiple devices may lead to models that can be used by clinicians and basic scientists to make inferences about the daily lifestyle and its effects on health and disease.",[244],[244,275,276,277,278],"Wearable Device","FitBit","Garmin","Apple Watch","2026-06-12",{"date":281,"type":34},"2026-06-16",{"date":256,"type":23},{"date":258,"type":23},{"name":40,"class":41},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":301,"leadSponsor":302,"locationsCount":42},"100629191","centered-surgery---preoperative-counseling-and-patient-satisfaction-100629191","NCT07471464","Centered Surgery - Preoperative Counseling and Patient Satisfaction","Inclusion Criteria:\n\n* Age \\>18y\n* Has decision-making capacity and able to provide informed consent for research participation\n* For patients undergoing SMA: Has active MyChart\n* Able to speak and read English\n\nExclusion Criteria:\n\n* Unable to consent",{"count":292,"type":23},106,"This study is a prospective cohort study which aims to assess patient satisfaction and preparedness for surgery through two methods of preoperative counseling: standard individual phone calls versus virtual group sessions called Shared Medical Appointments (SMAs). The study will focus on patients undergoing urogynecology prolapse surgeries at Cleveland Clinic. Researchers hypothesize that virtual group counseling will improve patient satisfaction and preparedness compared to individual phone calls. Additionally, the study will evaluate healthcare resource utilization as a secondary outcome.\n\nParticipants will complete surveys before and after surgery to measure satisfaction and preparedness using validated tools. The study will enroll patients aged 18 and older who can provide informed consent and are scheduled for specific prolapse surgeries. Findings may help improve preoperative counseling practices and enhance patient-centered care.",[295],"Pelvic Organ Prolapse",[297],"surgical counseling","2026-06-11",{"date":279,"type":34},{"date":298,"type":34},{"date":38,"type":23},{"name":40,"class":41},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":24,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":42},"100620878","nifedipine-and-enalapril-vs-nifedipine-and-labetalol-for-the-treatment-of-postpartum-hypertension-study-100620878","NCT07363343","Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study","Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NEPHRON)","NEPHRON","Inclusion Criteria:\n\n* Postpartum women aged 18 years or older\n* Clinical diagnosis of hypertensive disorder in pregnancy (gestational hypertension, chronic hypertension, preeclampsia with or without severe features)\n* Taking Nifedipine 60 mg every 12 hours for blood pressure control\n* Persistently elevated blood pressure at\u002Fabove 140\u002F90 mmHg in a 24-hour time period or have one or more severe range blood pressure at\u002Fabove 160\u002F110 mmHg requiring a second antihypertensive medication\n* English speaking\n\nExclusion Criteria:\n\n* Taking ≥2 antihypertensive agents during pregnancy\n* Heart block\n* Heart rate \\\u003C60 or \\>120 beats per minute\n* Heart failure\n* Creatinine \\>1.5 mg\u002FdL\n* Renal artery stenosis\n* Active connective tissue disease\n* Cerebrovascular accident\n* Failed treatment or contraindications to nifedipine, enalapril or labetalol",{"count":312,"type":23},200,[26],"To determine if nifedipine and enalapril will have better blood pressure control in the postpartum setting compared to nifedipine and labetalol.",[316,317],"Hypertension","Postpartum Preeclampsia",{"date":279,"type":34},{"date":320,"type":34},"2026-03-10",{"date":322,"type":23},"2029-12-31",{"name":40,"class":41},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":24,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":42},"100539044","improving-total-knee-arthroplasty-dissatisfaction-through-a-personalized-approach-focusing-on-proms-phenotypes-100539044","NCT06298721","Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs Phenotypes","Improving Total Knee Arthroplasty Dissatisfaction at 1-year Through a Personalized Approach Focusing on PROMs Phenotypes: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Adult subject (Age \\>18 and \\\u003C 80 years of age)\n2. The subject is proficient in the English language\n3. The patient is voluntarily prepared to sign the 'Informed Consent Form'\n4. The patient is scheduled for a unilateral primary TKA\n5. TKA PROMs Phenotypes with higher risk of dissatisfaction\n6. Patient is willing and able to complete the protocol required follow-up\n\nExclusion Criteria:\n\n1. Patient requires simultaneous or staged bilateral knee replacements, staged \\\u003C90 days apart\n2. Patients undergoing revision TKA\n3. Inflammatory arthritis\n4. History of infection in the joint undergoing TKA\n5. Patient is considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.)","80 Years",{"count":333,"type":23},300,[26],"This study is a randomized controlled trial to assess whether the implementation of a TKA Personalized Outcome Prediction Tool to set expectation, in addition to targeted interventions to address patients with poor baseline mental health and poor physical function, improves satisfaction at 1-year (when compared to standard of care).",[337,338,339],"Knee Osteoarthritis","Knee Arthropathy","Surgery","2026-06-09",{"date":298,"type":34},{"date":343,"type":34},"2024-03-12",{"date":345,"type":23},"2027-03-01",{"name":40,"class":41},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":24,"phases":357,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":369,"locationsCount":42},"100438503","phase-3-bone-marrow-aspirate-concentrate-versus-triamcinolone-injection-for-hip-osteoarthritis-100438503","NCT04990128","Bone Marrow Aspirate Concentrate Versus Triamcinolone Injection For Hip Osteoarthritis","Randomized Trial on the Evaluation of the Effectiveness of One Single Bone Marrow Aspirate Hip Injection Versus Triamcinolone for Hip Osteoarthritis","Inclusion:\n\n1. Provision of signed and dated consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged between 18 - 75 years old\n4. WOMAC Pain Subscale Total Score of 5 or higher in the Likert Scale (total score is 20)\n5. Kellgren-Lawrence Grade ≥ 2 on Hip X-Rays\n6. Body Mass Index ≤ 35 kg\u002Fm\\^2\n7. Unilateral or Bilateral Hip Osteoarthritis\n8. Prior physical therapy treatment for 6 weeks in the last 12 months and compliance with home exercise program\n9. Agreement to adhere to Lifestyle Considerations\n10. Discontinuation of pain\u002Fanti-inflammatory medications 2 week prior to baseline measurements\n11. Patients with cancer in remission for at least 5 years. Specific cancers which were treated with surgical resection and are not undergoing chemotherapy\u002Fradiation therapy such as breast cancer, colon cancer, or skin cancer, and others could participate when deemed in remission for 1 year. Written approval from oncologist will be necessary prior to enrollment\n12. Negative gram stain result\n\nExclusion:\n\n1. Prior corticosteroid injection to the hip\n2. History of hip replacement(s)\n3. Noncompliance to preventive screening tests for cancer indicated by age\n4. Active autoimmune disease\n5. Current use of oral corticosteroid\n6. Use of immunosuppressive medications, or who are known to me immunocompromised\n7. Inability to be weaned of oral anti-inflammatory medications\n8. History of Diabetes or HbA1c ≥ 6.5%\n9. Uncontrolled Thyroid Dysfunction: 0.450 uIU\u002FmL ≥ TSH levels ≥ 4.500 uIU\u002FmL\n10. Vitamin D Level \\\u003C 30 ng\u002Fml\n11. Anemia (Hgb \\\u003C 11.7 g\u002FdL for Women; Hgb \\\u003C 13 g\u002FdL for men)\n12. eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m\\^2\n13. Thrombocytopenia with platelet count less than 150,000 x 10\\^9 L\n14. Patients with coagulopathies based on known clotting disorder\n15. Patients currently on anti-coagulation therapies\n16. Patients who report any active infection(s) including cellulitis, TB, HIV, COVID, Hepatitis B and C\n17. Moving over the next year\n18. Inability to consent to the research study\n19. Inability to complete forms electronically\n20. Subjects in any other clinical trials\n21. History of allergic reaction to lidocaine\n22. Pregnancy or planning to be pregnant during trial\n23. Breastfeeding","75 Years",{"count":356,"type":23},100,[358],"PHASE3","This is a single site, randomized single blinded, two arm study researching the effects of bone marrow aspirate concentrate (BMAC) versus Triamcinolone in patients with hip osteoarthritis. The aims and hypothesis are as follows:\n\nSpecific Aim 1: Evaluate the change in pain and functional scores of a single bone marrow aspirate injection in comparison to triamcinolone in patients with hip osteoarthritis through validated patient reported outcomes scores at baseline to 12 months (6 weeks, 3 months, 6 months, and 12 months).\n\nHypothesis: The investigators hypothesize that triamcinolone and BMAC groups will have pain reduction after each respective intervention. The changes with triamcinolone will be noticeable on the short term. The BMAC changes will take longer to have an effect but will longer duration. The investigators hypothesize that at 6 months and 1 year participants receiving BMAC will have better scores reported on the WOMAC compared to the triamcinolone injection and better than prior to injection.\n\nSpecific Aim 2: Evaluate the change of bone marrow aspirate injection in comparison to triamcinolone in participant's performance on the 6 minute walk test from baseline to 12 months (6 weeks, 3 months, 6 months, and 12 months).\n\nHypothesis: The investigators hypothesize that there will be higher walking distances on the 6 minute walk test in the participants receiving a BMAC injection in comparison to triamcinolone starting at the 3 months follow-up time.\n\nSpecific Aim 3: Quantify and correlate cell characterization with patient reported outcomes score.\n\nHypothesis: The investigators hypothesize that there will be better patient reported outcomes in patients who have a higher concentration of mesenchymal stem cells injected.\n\nThe investigators will enroll 50 patients into each arm. Bone marrow will be aspirated then subsequently concentrated using the Emcyte PureBMC kit. The investigators will test the BMAC viability, rapid sterility, platelet concentration, volume, and total nucleated cell counts prior to injecting. The BMAC will be utilized as a hip injection into the affected hip of the patient.\n\nPatients receiving the Triamcinolone will undergo a sham bone needling to simulate the aspiration to keep patients blinded. Both groups will receive their injections under ultrasound guidance.",[361],"Hip Osteoarthritis",[363,364],"bone marrow aspirate concentrate","triamcinolone",{"date":298,"type":34},{"date":153,"type":23},{"date":368,"type":23},"2027-11",{"name":40,"class":41},{"id":371,"slug":372,"hasResults":12,"nctId":373,"briefTitle":374,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":12,"sex":51,"minAge":377,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":24,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":395},"100495034","assisted-ambulation-to-improve-health-outcomes-for-older-medical-inpatients-100495034","NCT05725928","Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients","Randomized Trial of Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria listed below to participate in this study:\n\n1. ≥65 years of age\n2. Admitted to a medical service\n3. Complete history and physical examination on file\n4. 6-Clicks score of 16-23\n5. Insurance with Traditional Medicare or Medicare Advantage\n\nExclusion Criteria:\n\nAny patient meeting any of the exclusion criteria listed below at baseline will be excluded from study participation:\n\n1. Significant language barrier that requires a translator (other than Spanish at Baystate site only)\n2. Discharge planned for that day or the following day\n3. Observation status\n4. Surgical procedure planned\n5. Patients diagnosed with unstable angina or other medical conditions precluding participation in exercise\u002Fambulation\n6. Permanent residence in a skilled nursing facility\n7. Comfort care measures only\n8. \\>48 hours since admission\n9. Active infection with COVID-19\n10. Other active infection requiring contact or droplet precautions\n11. Order for bedrest","65 Years",{"count":379,"type":23},3000,[26],"The investigator proposes to conduct a randomized trial of supervised ambulation delivered by mobility technician (MT) up to three times daily, including weekends, to hospitalized medical patients. The aims of the study are to compare the short and intermediate-term outcomes of patients randomized to the intervention versus those patients randomized to receive usual care, to identify patients who are most likely to benefit from the intervention and to assess whether the intervention increases or decreases overall costs of an episode of care, including the cost of the MTs, the index hospitalization and the first 30 days post enrollment.",[383,384,385,386],"Mobility Limitation","Frailty","Hospital Acquired Condition","Weakness, Muscle","2026-06-05",{"date":389,"type":34},"2026-06-08",{"date":391,"type":34},"2023-05-15",{"date":393,"type":23},"2026-12-01",{"name":40,"class":41},5,{"id":397,"slug":398,"hasResults":12,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":4,"eligibilityCriteria":402,"healthyVolunteers":12,"sex":51,"minAge":403,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":24,"phases":407,"briefSummary":408,"conditions":409,"keywords":415,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":429,"locationsCount":42},"100640620","youth-suicide-prevention-cams-bi-vs-safety-planning-in-a-randomized-trial-100640620","NCT07628192","Youth Suicide Prevention: CAMS-BI vs. Safety Planning in a Randomized Trial","Innovating Suicide Preventative Care for Youth; A Randomized Trial of CAMS- BI Versus Stanley- Brown Safety Planning Intervention in Preventing Suicide Driven Readmission","Inclusion Criteria:\n\n* Adolescents aged 12-17 years.\n* Admitted to inpatient psychiatry for suicide attempt or active suicidal ideation.\n* English-speaking patient and parent\u002Fguardian.\n* Ability to understand and the willingness to sign a written informed assent document with a parent\u002Fguardian willing and able to sign a written informed consent.\n\nExclusion Criteria:\n\n* Moderate or severe intellectual disability (IQ less than 70 and those patients in special education classes full time).\n* Schizophrenia or history of any type of psychosis including mood related psychosis and brief reactive psychosis.\n* In custody of Children's Services.","12 Years","17 Years",{"count":406,"type":23},118,[26],"This study outlines a randomized controlled trial evaluating two brief suicide-specific interventions for adolescents aged 12-17 who are hospitalized for suicidal ideation or attempts. Suicide remains a leading cause of death among youth, and many adolescents are discharged from inpatient care without targeted, suicide-focused treatment, contributing to high rates of readmission and ongoing risk. This study seeks to address that gap by comparing the effectiveness of the Collaborative Assessment and Management of Suicidality-Brief Intervention (CAMS-BI) with the Stanley-Brown Safety Planning Intervention (SPI), both delivered as single-session interventions during inpatient hospitalization.\n\nParticipants (N=118) will be randomly assigned to receive either CAMS-BI or SPI. CAMS-BI is a therapeutic, collaborative framework that focuses on identifying and addressing the underlying psychological drivers of suicidality, while SPI is a structured, practical approach that emphasizes immediate safety through coping strategies, support systems, and means restriction. Following the intervention, participants will be monitored for 90 days post-discharge, with follow-ups at 30, 60, and 90 days.\n\nThe primary outcome is the rate of psychiatric readmissions and suicide-related emergency department visits within 90 days of discharge. Secondary outcomes include changes in suicidal ideation, measured by the Beck Scale for Suicide Ideation, and caregiver confidence in managing their child's safety. Additional measures include distress levels, hopelessness, treatment satisfaction, and engagement.\n\nThe study hypothesizes that CAMS-BI will result in lower readmission rates, greater reductions in suicidal ideation, and improved caregiver confidence compared to SPI. Both interventions produce individualized safety or stabilization plans that are shared with patients and caregivers and incorporated into discharge planning to support continuity of care.\n\nSafety protocols are emphasized throughout the study, given the high-risk population. Participants receive standard clinical care, crisis resources, and close monitoring, with procedures in place to address any escalation in suicide risk. Data will be collected using secure systems, and confidentiality will be maintained through de-identification and controlled access.\n\nOverall, this study aims to determine whether a rapid, inpatient, suicide-focused intervention can improve short-term outcomes for high-risk youth and reduce the likelihood of rehospitalization, ultimately informing scalable approaches to suicide prevention in clinical settings.",[410,411,412,413,414],"Suicidal Ideation","Suicide Attempt","Safety Plan","Depression \u002F Major Depressive Disorder","Hopelessness",[416,417,418,419,420,421,422,414],"Youth suicide","Suicide ideation","Suicide attempt","Suicidal behavior","Depression","CAMS therapy","Safety plan","2026-06-03",{"date":425,"type":34},"2026-06-04",{"date":427,"type":23},"2026-08-01",{"date":345,"type":23},{"name":40,"class":41},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":439,"conditions":440,"keywords":442,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":42},"100617175","viability-assessment-using-fmn-measured-in-perfusate-and-bile-during-normothermic-machine-perfusion-100617175","NCT07315204","Viability Assessment Using FMN Measured in Perfusate and Bile During Normothermic Machine Perfusion","Viability Assessment Using Flavin Mononucleotide (FMN) Measured in Perfusate and Bile During Normothermic Machine Perfusion: an International, Multi-center Validation Study","Inclusion Criteria:\n\n* Age \\>18 years\n* Any graft type (DBD or DCD)\n* Any underlying recipient disease (i.e., end stage, liver tumour)\n* Any other donor risk factors and static cold storage time prior to NMP accepted by the participating center for transplantation in context of OrganOx metra use\n* Patients undergoing primary deceased donor liver transplantation where back-to-base NMP is used (OrganOx metra) from July 15, 2025 to December 31, 2027. (CCF only)\n* Patients who have undergone deceased donor liver transplantation where back-to-base NMP was used (OrganOx metra) from October 22, 2022 to July 14, 2025. (CCF only)\n\nExclusion Criteria:\n\n* Patients receiving a liver graft that is not perfused with OrganOx metra\n* Pediatric recipients (\\\u003C18years)\n* Patients listed for super urgent liver transplantation due to acute liver failure\n* Patients receiving combined organ transplant (heart+liver, lung+liver, liver+kidney, liver+intestine)\n* Patients receiving living donor liver transplant or a split (or reduced) liver transplantation or a domino graft.\n* Re-transplantations",{"count":438,"type":23},850,"Discarded perfusate samples will be collected from donors after circulatory death (DCD) or donors after brain death (DBD) organs during the machine perfusion period prior to transplantation by the study team. FMN will be measured as is standard of care for all machine perfusion liver transplant cases at Cleveland Clinic.\n\nParticipating centers will be provided with sample collection and shipping instructions to ensure sample preservation in accordance with IATA guidelines. Samples from outside sites will not be stored for future research and will be discarded once analysis is completed.\n\nAfter the collection of the samples from machine perfusion, the transplant procedure will continue according to standard process.",[441],"Liver Transplant Disorder",[443,444,445,446,447],"normothermic machine perfusion","flavin mononucleotide","graft viability","liver transplant","OrganOx metra","2026-06-02",{"date":425,"type":34},{"date":451,"type":34},"2026-03-13",{"date":453,"type":23},"2028-12-31",{"name":40,"class":41},{"id":456,"slug":457,"hasResults":12,"nctId":458,"briefTitle":459,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":462,"targetDuration":4,"studyType":24,"phases":464,"briefSummary":465,"conditions":466,"keywords":468,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":472,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":476,"locationsCount":42},"100592207","closm-trial-groin-closure-using-layered-option-for-suture-material-100592207","NCT06990425","CLOSM Trial: Groin Closure Using Layered Option for Suture Material","CLOSM","Inclusion Criteria:\n\n* All patients \\> 18 years who undergo ELECTIVE vascular surgery that would require groin incisions\n* Patients with to undergo ELECTIVE bilateral groin incisions will be matched to receive closure with PDS in one groin and Vicryl in the other groin\n\nExclusion Criteria:\n\n1. Age 17 or younger\n2. Prisoners\n3. Pregnant patients\n4. Emergent cases\n5. Active groin infection prior to intervention\n6. History of prior surgical groin access (re-operative groin)\n7. Groin closure after extracorporeal membrane oxygenation (ECMO)",{"count":463,"type":23},259,[26],"This is a randomized controlled trial comparing groin closure after vascular intervention with Vicryl suture versus PDS (polydioxanone) suture. This will be a single center trail performed at CCF main campus. Patients will be enrolled in a prospective fashion and will be randomized 1:1 to either PDS or Vicryl closure. Patients undergoing bilateral groin exposure will be randomized to receive both closure types to either groin.",[467],"Vascular Diseases",[469,470,471],"surgical site complication","vascular surgery","wound healing",{"date":423,"type":34},{"date":474,"type":34},"2025-03-27",{"date":38,"type":23},{"name":40,"class":41},{"id":478,"slug":479,"hasResults":12,"nctId":480,"briefTitle":481,"officialTitle":481,"acronym":4,"eligibilityCriteria":482,"healthyVolunteers":17,"sex":51,"minAge":483,"maxAge":331,"enrollmentInfo":484,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":493,"leadSponsor":495,"locationsCount":42},"100288134","corneal-elastography-and-patient-specific-modeling-100288134","NCT03030755","Corneal Elastography and Patient Specific Modeling","Inclusion Criteria:\n\n* Any patient with keratoconus diagnosed by standard criteria, including topographic steepness, irregular astigmatism with a pattern consistent with keratoconus.\n* Any patient deemed a candidate for LASIK (laser vision correction) and scheduled for surgery.\n\nExclusion Criteria:\n\n* Inability to provide informed consent, including non-English speaking (if interpreter not available) and cognitively\u002Fmentally impaired (if legal guardian not available).","16 Years",{"count":241,"type":23},"The goal of this research is to develop measurement tools and simulation technology for characterizing and predicting individual responses to corneal treatments and for advancing understanding of corneal ectasia risk factors. Patients who either 1) have keratoconus and are being evaluated for corneal crosslinking or 2) have refractive error and are being evaluated for refractive surgery procedures such as LASIK will have their eyes imaged to assess their mechanical properties and will have computational simulations performed to predict the response to treatment. One aim of the study is to test the hypothesis that computational models can predict the cornea's shape changes within clinically acceptable limits of error.",[487,488,489],"Cornea; Ectasia","Refractive Errors","Keratoconus",{"date":423,"type":34},{"date":492,"type":4},"2016-05",{"date":494,"type":23},"2027-05",{"name":40,"class":41},{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":502,"eligibilityCriteria":503,"healthyVolunteers":17,"sex":18,"minAge":504,"maxAge":505,"enrollmentInfo":506,"targetDuration":4,"studyType":24,"phases":508,"briefSummary":509,"conditions":510,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":518,"locationsCount":42},"100634312","single-visit-clinical-validation-of-screenfire-a-low-cost-hpv-test-efficacy-and-cost-effectiveness-phase-2-100634312","NCT07538050","Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (Phase 2)","Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (Phase 2)Single Visit Clinical Validation of ScreenFire, a Low-Cost HPV Test: Efficacy and Cost Effectiveness (Phase 2)","SCALE AIM 2","Inclusion Criteria:\n\n* Women between 30-59 years of age\n* Willing to conduct HPV self-sampling\n\nExclusion Criteria:\n\n* Prior hysterectomy\n* HPV testing in at least 5 years\n* Previous diagnosis or treatment of invasive cancer","30 Years","59 Years",{"count":507,"type":23},1000,[26],"In high-income countries, prevention strategies have led to declines in cervical cancer rates by more than 75% in high-income countries. In contrast, low- and middle-income countries (LMICs) carry the global burden of cervical cancer with about 85% of new cases and 90% mortality. Screening is an essential component of effective prevention to reduce this disease burden. The World Health Organization recommends human papillomavirus (HPV) testing as the most effective screening method. However, HPV testing can be expensive and complex to implement. Most tests require central laboratory processing, which means women must come back for a different visit to obtain results and potential treatment. In LMICs, this often results in high loss to follow up because many women face transportation and other challenges. The development of new, low-cost HPV tests that can be processed locally as the potential to improve adherence in screening programs. In this study, the research team will assess the feasibility of a same-day screen-and-treat approach compared to the standard two-visit regime in the context of the cervical cancer prevention program in El Salvador. This will be a cross-sectional study that will enroll 1,000 women in remote areas of the country over 10-15 weeks. The hypothesis is that at least 10% fewer women lost to follow-up at six months using the single visit approach compared to the \\>20% historical loss to follow-up using the standard two-visit approach.",[511],"Cervical Cancer Screening","2026-05-27",{"date":514,"type":34},"2026-05-28",{"date":516,"type":34},"2026-04-16",{"date":38,"type":23},{"name":40,"class":41},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":525,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":527,"targetDuration":4,"studyType":24,"phases":529,"briefSummary":530,"conditions":531,"keywords":534,"overallStatus":199,"whyStopped":4,"lastUpdateSubmitDate":539,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":542,"leadSponsor":544,"locationsCount":545},"100624619","shape-sensing-versus-electromagnetic-robotic-bronchoscopy-for-evaluation-of-pulmonary-lesions-100624619","NCT07411989","Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions","Shape-sensing Versus Electromagnetic Robotic Bronchoscopy for Evaluation of PulmoNary LEsions: the SERENE Trial","SERENE","Inclusion Criteria:\n\n1. ≥ 18 years of age at time of bronchoscopy\n2. Scheduled for navigational bronchoscopy for the evaluation of pulmonary lesion\n\nExclusion Criteria:\n\n1\\. Inability to provide informed consent",{"count":528,"type":23},346,[26],"This is an investigator-initiated, multicenter, non inferiority, cluster randomized controlled trial. The primary objective is to compare the diagnostic yield of the electromagnetic robotic assisted bronchoscopy with digital tomosynthesis (Galaxy system by Noah Medical) to the shape sensing robotic assisted bronchoscopy with integrated cone beam CT (Ion™ Endoluminal System by Intuitive) in patients undergoing bronchoscopy for peripheral pulmonary lesion (PPL) evaluation.",[532,533],"Peripheral Pulmonary Lesions (PPLs)","Lung Nodules",[535,536,537,538],"Bronchoscopy","Peripheral Pulmonary Lesions","Robotic assisted bronchoscopy","Lung biopsy","2026-05-26",{"date":514,"type":34},{"date":114,"type":23},{"date":543,"type":23},"2028-12",{"name":40,"class":41},2,{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":4,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":553,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":555,"conditions":556,"keywords":558,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":42},"100638528","at-home-bowel-stimulation-100638528","NCT07574437","At-Home Bowel Stimulation","At-Home Bowel Stimulation: A Prospective Cohort Study","Inclusion Criteria:\n\n\\- Adult patients who have undergone a partial colectomy or proctectomy for benign or malignant disease with a protective loop ileostomy\n\nExclusion Criteria:\n\n* Underlying inflammatory bowel disease (IBD)\n* Known peritoneal metastases at the time of ileostomy closure\n* Inability to provide clear and informed consent\n* History of subtotal colectomy or total proctocolectomy\n* Planned laparotomy for ileostomy closure\n* Inability to speak English or Spanish",{"count":554,"type":23},34,"Postoperative ileus (POI) is a common complication after ileostomy closure and is associated with patient discomfort, delayed return of bowel function, prolonged hospital stay, and increased healthcare costs. One proposed contributor to POI is prolonged inactivity of the bowel segment distal to the ileostomy prior to restoration of intestinal continuity.\n\nPrevious studies, including a multicenter randomized controlled trial, have shown that preoperative bowel stimulation of the defunctionalized intestine can reduce rates of POI and shorten length of hospital stay. However, these interventions were performed in outpatient or hospital settings and required specialized nursing support.\n\nThis single-center, prospective interventional study aims to evaluate the feasibility and clinical impact of a patient-performed, at-home bowel stimulation program prior to ileostomy closure. Participants will perform daily bowel stimulation sessions at home for 3 weeks before surgery, following an initial supervised session. The primary objective is to assess feasibility, defined as successful completion of at least 6 of 9 at-home stimulation sessions by more than 75% of participants. Secondary outcomes include return to normal bowel function and length of hospital stay. Exploratory outcomes include postoperative bowel function, quality of life, and patient satisfaction.\n\nStudy outcomes will be compared with a retrospective cohort of patients who previously underwent ileostomy closure without at-home bowel stimulation. The long-term goal of this research is to support incorporation of preoperative bowel stimulation into Enhanced Recovery After Surgery (ERAS®) pathways for patients undergoing ileostomy closure.",[557],"Post-Operative Ileus (POI)",[559,560],"Post-operative ileus","Bowel stimulation","2026-05-18",{"date":563,"type":34},"2026-05-20",{"date":565,"type":34},"2025-10-28",{"date":567,"type":23},"2026-07-07",{"name":40,"class":41},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":12,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":576,"targetDuration":578,"studyType":146,"phases":4,"briefSummary":579,"conditions":580,"keywords":585,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":594,"lastUpdatePostDateStruct":595,"startDateStruct":597,"completionDateStruct":599,"leadSponsor":601,"locationsCount":42},"100485269","global-cardio-oncology-registry-100485269","NCT05598879","Global Cardio Oncology Registry","G-COR","Inclusion Criteria:\n\n* New cardio-oncology consultation for breast cancer patients, or\n* New cardio-oncology consultation for Hodgkin's or non-Hodgkin's lymphoma patients, or\n* New cardio-oncology consultation for acute or chronic leukemia patients, or\n* New cardio-oncology consultation for multiple myeloma or AL amyloidosis, or\n* New cardio-oncology consultations for immune check-point inhibitors cardiac evaluation.\n* All patients have to be 18 years old or older\n\nExclusion Criteria:\n\n* Cardio-oncology patients who have previously had cardio-oncology evaluation and follow up by the investigators.\n* Minors less than 18 years old.\n* Inability or unwillingness to consent to participate",{"count":577,"type":23},5000,"24 Months","G-COR is the first Global Prospective Cardio-Oncology Registry. It is a multinational, multicenter prospective observational cohort registry, with the goal of collecting clinical, laboratory, imaging, demographic, and socioeconomic data to identify risk factors associated with increased incidence of cancer therapy related cardiovascular toxicity (CTR-CVT) in different settings and to derive and validate risk scores for cardio oncology patients treated in different geographic locations throughout the world.",[581,582,583,584,149],"Breast Cancer","Hematologic Malignancy","Immune Checkpoint Inhibitor-Related Myocarditis","Cardiotoxicity",[586,587,588,589,590,591,592,593],"cardiotoxicity","Cancer related cardiovascular diseases","prospective registry","international collaboration","social determinants of health","health care disparities","real world data","cardiology-oncology team work","2026-05-07",{"date":596,"type":34},"2026-05-12",{"date":598,"type":34},"2022-07-01",{"date":600,"type":23},"2029-07-01",{"name":40,"class":41},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":17,"sex":51,"minAge":19,"maxAge":4,"enrollmentInfo":610,"targetDuration":611,"studyType":146,"phases":4,"briefSummary":612,"conditions":613,"keywords":622,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":42},"100489526","development-of-circ-technologies-100489526","NCT05654272","Development of CIRC Technologies","Development of Cardiovascular Innovation Research Technologies","CIRC","Inclusion Criteria:\n\n* Age ≥ 18 years of age\n* Provision of written informed consent\n* If not healthy volunteer, must be diagnosed with cardiovascular disease\n\nExclusion Criteria:\n\n* Vulnerable populations will be excluded from this study including Prisoners\n* Other contraindications to CMR imaging to be determined by standard MRI protocols\n* Decisionally impaired (e.g., dementia or cognitive disability)",{"count":507,"type":23},"20 Years","Cardiovascular disease is the leading cause of death worldwide. Advanced cardiovascular imaging using Magnetic Resonance Imaging (MRI) has proven to be effective in providing gold standard myocardial tissue characterization. Moreover, the intrinsic advantage of MRI's lack of exposure to ionizing radiation is particularly beneficial. At the same time, blood work can be very useful in early detection of certain cardiomyopathy, such as amyloid. However, there is a lack of agreement of on which markers are the most sensitive. This multi-study will allow us the unique opportunity to form a more comprehensive understanding for various cardiovascular diseases.\n\nOur team has developed novel cardiac MRI techniques that leverages endogenous tissue properties to reveal a milieu of deep tissue phenotypes including myocardial inflammation, fibrosis, metabolism, and microstructural defects. Among these phenotypes, myocardial microstructure has proven to be most sensitive to early myocardial tissue damage and is predictive of myocardial regeneration. In this study, the investigators aim to further study the importance of cardiac microstructure revealed by MRI in patient and healthy population and compare this novel technology with conventional clinical biomarkers.",[149,244,614,615,616,617,618,619,620,621],"Ischemic Heart Disease","Non-ischemic Cardiomyopathy","Valvular Heart Disease","Metabolic Cardiomyopathy","Congenital Heart Disease","Aortic Diseases","Atrial Fibrillation","Ventricular Fibrillation",[623],"MRI","2026-05-06",{"date":626,"type":34},"2026-05-08",{"date":628,"type":34},"2022-09-09",{"date":630,"type":23},"2042-09-09",{"name":40,"class":41},""]